




Dear Pharmacist,

With so many insulin formulations available today, it is important to differentiate between the analog and human insulins. This is especially true for premixed insulin formulations, because not all premixed insulins are the same!

There are important differences between

**NovoLog® Mix 70/30** (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin])—a premixed insulin analog—and human 70/30 insulin formulations. For example, **NovoLog® Mix 70/30** contains no NPH insulin. **NovoLog® Mix 70/30** begins acting faster and is dosed within 15 minutes of starting a meal, while human 70/30 insulin is taken 30 minutes before a meal. Thirty percent of **NovoLog® Mix 70/30** is available to work immediately and 70% is engineered for extended action (up to 24 hours).



What's more, **NovoLog® Mix 70/30** is available in prefilled, disposable **NovoLog® Mix 70/30 FlexPen®**. In two separate studies, **NovoLog® Mix 70/30 FlexPen®** was preferred by nearly 75% of patients over a competitor's pen, as well as over vial and syringe.<sup>1,2\*</sup>

**NovoLog® Mix 70/30 FlexPen®** is available for use with **NovoFine®** 30- or 31-gauge disposable needles, designed to help improve injection comfort.

NovoLog® Mix 70/30 is indicated for the treatment of patients with diabetes mellitus for the control of hyperglycemia. NovoLog® Mix 70/30 is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® Mix 70/30 or one of its excipients. Hypoglycemia is the most common adverse effect of all insulin therapies, including NovoLog® Mix 70/30. As with other insulins, the timing of hypoglycemia may differ among various insulin formulations. Because NovoLog® Mix 70/30 has peak pharmacodynamic activity 1 hour after injection, it should be administered with meals. The rate of insulin absorption and consequently the onset of activity is known to be affected by the site of injection, exercise, and other variables.

Potential side effects associated with the use of all insulins include hypoglycemia, hypokalemia, lipodystrophy, and allergic reactions. Because of differences in the action of NovoLog® Mix 70/30 and other insulins, care should be taken in patients in whom these conditions may be clinically relevant (eg, patients who are fasting, have autonomic neuropathy, are using potassium-lowering drugs, or are taking drugs sensitive to serum potassium level).

Dose regimens of NovoLog® Mix 70/30 will vary among patients and should be determined by the health care professional familiar with the patient's metabolic needs, eating habits, and other lifestyle variables. Do not mix NovoLog® Mix 70/30 with any other insulin product.

Any change in insulin should be made cautiously and only under medical supervision.

Thank you for taking time to ensure that the proper premixed insulin is dispensed correctly. We encourage you to visit the Institute for Safe Medication Practices at ISMP.org for information about preventing look-alike or sound-alike dispensing errors. For more information on **NovoLog® Mix 70/30**, call Novo Nordisk at **1-800-727-6500**, Monday–Friday, 8 am to 7 pm EST, or visit **novologmix70-30.com**.

Best regards,

Novo Nordisk

\*Based on multicenter trials comparing NovoLog® Mix 70/30 FlexPen with lispro mix 75/25 pen<sup>1</sup> and vial and syringe.<sup>2</sup>

**References:** 1. Niskanen L, Jensen LE, Råstam J, Nygaard-Pedersen L, Erichsen K, Vora JP. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. *Clin Ther.* 2004;26:531-540. 2. Korytkowski M, Bell D, Jacobsen C, Suwannasari R, for the FlexPen® Study Team. A multicenter, randomized, open-label, comparative, twoperiod crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. *Clin Ther.* 2003;25:2836-2848.

**Please visit [novologmix.com](http://novologmix.com) for full prescribing information**

FlexPen, NovoFine, and NovoLog are registered trademarks of Novo Nordisk A/S.

© 2007 Novo Nordisk Inc. September 2007 132938